|
|
Portfolio Management: Best Practice in Optimizing Resource AllocationProduct Type: Market Research ReportPublished by: Datamonitor Published: June 2001 Product Code: R313-0057 Description As competition increases in this era of aggressive M&A activity, it is vital that the most profitable approach to portfolio management is taken. An ad hoc approach to product reviews, relying on the subjective expertise of management teams, offers insufficient insight to realize the true potential within a portfolio. Portfolio Management: Best Practice in Optimizing Resource Allocation is an in-depth evaluation of portfolio management modeling tools and strategies. Detailed analyses of quantitative and qualitative methods of reviewing R&D and marketed products are offered and best practice recommendations drawn, based on case studies of leading companies' strategies. Datamonitor Commercial Index, an interactive best practice model showing the key metrics for performing a portfolio review, is also included.Table of Contents EXECUTIVE SUMMARYReport summary Introduction Patient potential for vaccines Unmet needs in vaccine market Investors in vaccine market Indication focus Future market leaders R&D opportunities in vaccines DISEASE OVERVIEW Vaccine definition Passive immunization Active immunization Respiratory Syncitial Virus (RSV) Parainfluenza virus (PIV) Rotavirus Streptococcus pneumoniae Neisseria Meningitidis Influenza Lyme disease Helicobacter pylori Human papillomavirus (HPV) Varicella zoster virus (VZV) Cytomegalovirus Group A staphylococcus (GAS) Group B streptococcus (GBS) Chlamydia Herpes simplex virus (HSV) Epstein-Barr virus Diphtheria, tetanus and pertussis Hemophilus influenza type b Measles, mumps and rubella (MMR) Patient potential of vaccines Childhood vaccinations Other vaccinations Classification of pipeline products Clinical endpoints in disease Immunogenicity Efficacy Surrogate markers Unmet needs in vaccine market Lack of alternative delivery techniques Low efficacy New disease targets Poor safety profiles Refridgerator storage Manufacturing difficulties and risks VACCINE PIPELINE ANALYSIS Pipeline analysis by development strategy Key vaccine discovery strategies Key R&D protocol strategies in vaccines Key drug delivery strategies in vaccines Key licensing strategies in the vaccine industry Pipeline analysis by indication Pipeline analysis by region Pipeline analysis by company type Pipeline analysis by individual company VACCINE ANALYSIS Respiratory syncytial virus vaccines AHP's RSV subunit vaccine Fabre's recombinant RSV vaccine GSK adjuvant RSV vaccine (SBAS4) Parainfluenza virus vaccines Aviron's PIV3 vaccine Rotavirus Rotarix Bovine derived rotavirus Streptococcus pneumoniae QUILIMMUNE-P AHP PnCRM9 11 valent Pneumococcal Influenza vaccines FluMist Aventis' adjumer formulated influenza vaccines Herpes simplex vaccines Simplirix and adjuvant TA-HSV (& DISC HSV) MMR and VZV MMR-V (Merck) GSK's MMR-V Shingles vaccine Cytomegalovirus vaccine Chiron's gBMF59 Human papilloma virus Cantab TA-HPV MedImmune's MEDI-501 Merck's Virus-like particles (VLPs) Neisseria Meningitidis Components of combination vaccines Booster vaccine doses Key phase I development projects Cell-cultured Fluviral Aviron's EBV vaccine Key pre-clinical/research development projects Vaccine groups for which no marketed vaccine is yet available Vaccine groups for which a marketed vaccine does currently exist COMPARATIVE ANALYSIS Comparitive analysis of vaccines for which no current vaccine is marketed towards indicated disease Introduction Respiratory syncytial virus (RSV) Current treatment strategies Current prophylactic strategies Comparative analysis of developmental RSV vaccines and Synagis Parainfluenza virus Current theapeutic strategies Rotavirus Current theapeutic strategies Herpes Simplex virus Current therapeutic strategies Comparative analysis of developmental HSV vaccines and acyclovir Cytomegalovirus Congenital CMV Transplant CMV HIV retinitis Comparative analysis of developmental CMV vaccine and ganciclovir Human papillomavirus Comparative analysis of genital warts vaccine and Aldara cream Comparative analysis of cervical cancer vaccine and current treatment Comparitive analysis of vaccines for which marketed vaccine currently exists for disease indication Introduction Influenza Comparative analysis of developmental influenza vaccines and Fluad Streptococcus pneumonia MMR and VZV FUTURE FOCUS IN VACCINES Vaccine market drivers Future trends in populations Prospective vaccine launches Launch forecast methodology Forecast launches in vaccines from 2000 to 2007 Forecast methodology Predicting market share Forecasting future growth Influencing factors Influenza market forecast Influenza market sales forecast, 2000-2007 MMR and VZV market forecast MMRV/VZV market sales forecast, 2000-2007 Streptococcus pneumonia market forecast Streptococcus pneumonia market sales forecast, 2000-2007 Neisseria meningitidis vaccine market forecast Meningococcal market sales forecast, 2000-2007 Combination market forecasts Combination market sales forecasts Human papillomavirus market forecast HPV market sales forecasts, 2000-2007 CMV Market forecast CMV market sales forecasts, 2000-2007 Herpes simplex virus market forecasts HSV market sales forecasts, 2000-2007 Rotavirus market forecast Rotavirus vaccine market sales forecasts, 2000-2007 Parainfluenza virus vaccine market forecasts Parainfluenza virus market sales forecasts Respiratory syncytial virus vaccine market forecasts Respiratory syncytial virus market sales forecasts Long term potential of early phase vaccines APPENDIX Research programme methodology SPRINT databases Primary Research Quantification of Data Reliability Forecasting Methdology LIST OF TABLES LIST OF FIGURES (c) Datamonitor 2000. All Rights Reserved |
|
||||||||
MindBranch has been the leading provider of industry and investment research from more than 550 independent research firms since 1992. With over 90,000 market research reports, MindBranch is your trusted source of competitive business intelligence. |